There are already reports that F11R antagonists are therapeutic agents for the prevention and treatment of thrombosis, atherosclerosis, heart attacks, strokes, and other clinical disorders [27–30], but whether F11R antagonists can be used in treating malignant tumors is still prelimited. The gene discussed is F11R; the disease is atherosclerosis.